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This study describes the characteristics of the immune responses against adenovirus in C57BL/6 mice. CTL responses
could be induced against E1Bp of adenovirus type 5, when whole viruses were immunized. A panel of E1Bp-specific CTL
clones showed a wide range of T cell avidity. Recognition of the E1Bp peptide and a panel of variant peptides containing a
single alanine substitution by CTL clones revealed that the fine specificity of the CTL response was quite diverse, rather than
being limited to a certain clonal preference. Moreover, the variant peptides with a substitution at the TCR contact residue had
antagonistic properties to some of the CTL clones, while being agonistic to others, reflecting the extensive diversity of the T cells.
These results imply that the functional diversity of T cells to even a single epitope should be considered in manipulating immunityINTRODUCTION
CD8 cytolytic T lymphocytes (CTL) play a pivotal role
in protecting the host from viral infection (Doherty et al.,
1992). Although a large number of viral proteins encoded
in the infected host cell result in the generation of an
enormous number of antigenic peptides via antigen pro-
cessing, the CTL response is generally focused on a few
immunodominant epitopes (Yewdell and Bennink, 1999).
Studies of the TCR repertoire specific to a single an-
tigenic peptide have shown that some display a highly
diverse TCR V usage (Casanova et al., 1991; Horwitz et
al., 1994), whereas others are limited to specific TCR 
and  chains (Deckhut et al., 1993; Cose et al., 1995;
Lehner et al., 1995). However, the correlation between
the extent of the diversity of TCR repertoire and the
functional characteristics of immune response has not
been defined in detail.
The human adenovirus type 5 (Ad5) has been used as
a vector for gene transfer in vivo after rendering replica-
tion defective by deleting its early gene locus, E1, con-
stituted with the E1A and E1B region. Recombinant E1-
deleted adenoviral vectors are frequently used because
of their ability to infect a wide range of target cells with
a high efficiency. However, there are some limitations for
their in vivo applications, including transient gene ex-
pression, the development of adverse responses, such
as inflammation, and reduced gene expression following
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238a second administration (Yang et al., 1994a,b, 1996). This
results from the action of the host immune cells, espe-
cially CD8 T cells activated by the viral epitope ex-
pressed in adenoviral vector-transduced cells (Yang et
al., 1994a,b, 1996). The major antigenic epitope of the
E1-deleted vector causing cellular immunity remains un-
clear. However, it appears to be partly related to the fact
that E1 functions can be recovered in trans by E1-like
elements of the cellular genes under some special con-
ditions (Imperiale et al., 1984; Spergel et al., 1992) or by
contamination of E1-containing viruses during the con-
struction of E1-deleted viral vectors (Lochmuller et al.,
1994; Hehir et al., 1996; Yeh et al., 1996). In addition, since
a significant portion of individuals have experience of
infection or are under persistent infection with the wild-
type virus without any pathological symptoms, subse-
quent introduction of the viral vector may readily activate
the CTLs from the preexisting immunity against wild-type
virus (Schmitz et al., 1983; Piedra et al., 1998; Kremer et
al., 2000).
Recent reports raise the possibility of adenovirus in-
fections being fatal to immunocompromised individuals,
including bone marrow transplant recipients, AIDS pa-
tients, and even solid organ transplant recipients (Carri-
gan, 1997; La Rosa et al., 2001). Although effective anti-
viral therapy is not available in patients undergoing se-
vere adenovirus diseases, encouraging results have
recently been obtained from several clinical studies us-
ing unmanipulated donor lymphocytes for reconstituting
the immunodeficiency of transplant patients (Howard etto viruses and in developing adoptive immunotherapy for imm
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Despite the fact that adenoviruses are increasinglyunoco
onist; a
m on
recognized for their higher frequency of pathological
infection as well as clinical usage as gene-transferring
vectors, little is known regarding the characteristics of
the cellular immune response to immunodominant
epitopes of adenovirus. Previous studies have demon-
strated that the CTL response to Ad5 in mice was exclu-
sively directed against the Ad5E1A-encoded antigen in
H-2b mice (Rawle et al., 1991). An E1A-encoded CTL
epitope (SGPSNTPPEI, E1Ap) has been considered the
only immunodominant CTL epitope of Ad5 when immu-
nized with the whole virus (Kast et al., 1989, 1991). How-
ever, it was revealed that the Ad5E1B-derived peptide
(VNIRNCCYI, E1Bp) could also induce a strong CTL re-
sponse when immunized with Ad5E1-expressing tumor
cell lines in C57BL/6 mice (Toes et al., 1995). Further-
more, the immunogenicity of E1Bp was higher than that
of E1Ap, since CTL-mediated anti-Ad5E1 tumor response
was dominated by Ad5E1B-specific CTL (Toes et al.,
1996). However, it is not known whether E1Bp serves as
one of the immunodominant CTL epitopes when immu-
nized in the form of a wild-type virus.
In this study, an E1Bp-specific CTL population was
investigated to determine whether it could be induced
effectively in C57BL/6 mice when immunized with the
wild-type virus. In addition, the fine specificity and the
diversity of the TCR repertoire against Ad5E1Bp were
examined at the clonal level. The results in this study
showed that Ad5E1Bp-specific CTLs were elicited effec-
tively in C57BL/6 mice immunized with the wild-type
virus, and the E1Bp-specific TCR repertoire was quite
diverse at the level of not only TCR V usage but also its
functional specificity. Thus, complex and diverse CTL
responses to Ad5-derived immunodominant epitopes
should be taken into consideration for developing an
adoptive immunotherapy as well as the recombinant
adenoviral vector.
RESULTS
E1Bp-specific CTLs were induced efficiently in
C57BL/6 mice immunized with Ad5
Although the Ad5E1B-derived peptide E1Bp is well
defined as an immunodominant CTL epitope in C57BL/6
mice when they are immunized with Ad5E1-expressing
tumor cells, E1Bp immunogenicity has not yet been dem-
onstrated when delivered in the form of wild-type virus.
To examine the ability of C57BL/6 mice to induce E1Bp-
specific CTL responses when immunized with Ad5, an ex
vivo CTL assay was performed. When splenocytes from
immune mice were obtained and examined for their
cytolytic activity, they efficiently lysed EL-4 target cells
pulsed with E1Bp (Fig. 1A). These results suggest that
immunizing live viruses could also elicit E1Bp-specific
CTL responses in C57BL/6.
A panel of E1Bp-specific CTL clones was established,
as described under Materials and Methods, to investi-
gate the specificity and diversity of E1Bp-specific CTLs
induced by Ad5 infection. Cytotoxicity assays were car-
ried out with various target cells of different MHC back-
ground. Figure 1B shows data of 5F13, a representative
of the E1Bp-specific clones, and the other clones dis-
played similar results. Clone 5F13 recognized EL-4 or
FIG. 1. Generation of E1Bp-specific CTL populations and identifica-
tion of the E1Bp-specific CTL clones. (A) C57BL/6 mice were immu-
nized with Ad5 virus. The splenocytes were harvested 9 days later and
subjected to a cytotoxicity assay against EL-4 cells pulsed with 10 M
E1Bp (closed symbols). Untreated EL-4 cells were used as negative
controls (open symbols). (B) Clone 5F13, which was established as
described under Materials and Methods, was tested for cytolytic ac-
tivity against EL-4 (H-2b), RMA-S (H-2b), LB (H-2b/d), P815 (H-2d), and
YAC-1 pulsed with E1Bp in a standard 51Cr release assay (closed
symbols). Untreated cells were used as negative controls (open sym-
bols). The lysis values shown at the indicated E:T ratios represent the
average of triplicate experiments. (C) Clone 5F13 was stained with
FITC- or PE-conjugated anti-CD8, anti-CD4, anti-NK1.1, and anti-TCR
mAb and analyzed by flow cytometry.
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RMA-S cells pulsed with E1Bp, but not P815 or Yac-1
cells pulsed with the same peptide or nontreated EL-4
cells. When LB cells expressing both H-2b and H-2d
molecules were used as targets, the cytotoxicity was
less efficient than that when EL-4 or RMA-S cells ex-
pressing H-2b alone were used. These results indicate
that the CTL clones established in this study were H-2b
restricted and exerted cytotoxic activity in an antigen-
specific manner, ruling out involvement of other cytotoxic
cells, such as natural killer cells. The fact that the CTL
clones were of CD8CD4TCRNK1.1 phenotype (Fig.
1C) also supports the functional characteristics of the
clones and accordingly indicates that the CD8 T cells
were responsible for the cytotoxicity.
E1Bp-specific CTL clones showed diverse extents of
antigenic sensitivity
To determine whether there are any functional differ-
ences among these T cell clones, the antigenic sensitiv-
ity of each clone was analyzed by testing the capacity of
nine CTL clones to lyse EL-4 target cells pulsed with
various concentrations of E1Bp (0.0001–10 M). As
shown in Fig. 2A, clone 5F10 required E1Bp at a concen-
tration of 0.005 M to induce half-maximal lysis. In con-
trast, clone 5A3 required an approximately 200-fold
higher concentration of the peptide than 5F10 to induce
a comparable response, indicating that the E1Bp-spe-
cific CTL clones varied in antigenic sensitivity over a
wide range. To confirm these results, the clones were
examined for intracellular IFN- production after stimu-
lation with different E1Bp doses. The result obtained
from the intracellular IFN- staining method closely cor-
relates with that from the cytotoxicity assay in evaluating
the functional activity of CD8 T cells (Badovinac et al.,
2000). The clones were incubated either without peptide
or with E1Bp in the presence of the protein transport
inhibitor monensin. After 5 h, the extent of intracellular
IFN- produced by antigenic stimulation was analyzed
by flow cytometry after staining with anti-IFN- antibody.
Figure 2B shows the frequency of the responding cells of
each clone in response to various amounts of antigen.
The clones showed various antigen-dose responses to
produce IFN- after antigenic stimulation, which is con-
sistent with the data from the cytotoxicity assay. Clone
5F10 and 5F11 showed almost the maximum percentage
of IFN- secreting cells at an antigen concentration as
low as 1 nM, while clone 5A3 responded little at the
same antigenic stimulation. The CTL clones expressed
similar levels of T cell receptors (TCR) and CD8 mole-
cules (data not shown). Therefore, these results suggest
that the diverse sensitivity displayed by the clones was
due to differences in TCR avidity to the MHC/peptide
complex of each clone.
E1Bp-specific CTL clones showed diverse TCR
specificity structurally and functionally
The differences in TCR avidity might reflect differences
in the antigenic specificity of TCR. Thus, a series of
variant peptides containing a single alanine substitution
were used to analyze the fine specificity of the nine CTL
clones. The substitution at position 5 (P5, Asn), since it is
well known as a primary anchor residue of the Db bind-
ing peptides, was not included in this study. When the
binding affinity of these variant peptides to Db was ex-
amined with a TAP-deficient RMA-S cell by flow cytom-
etry, all substitutions of the cognate peptide residue
except P5 had little influence on Db binding (Fig. 3A).
It was reported that the stability of the peptide–MHC
FIG. 2. Antigenic sensitivity of CTL clones. The relative ability of the
CTL clones to recognize E1Bp was assessed in standard 51Cr release
assays (A) and intracellular IFN- staining assays (B). Cytotoxicity
assays were performed with nine CTL clones at an E:T ratio of 3:1. EL-4
pulsed with various concentrations of E1Bp were used as targets. The
lysis values represent the average of triplicate experiments. For intra-
cellular IFN- staining, the clones were rested for 8 days and incubated
with EL-4 pulsed with various concentrations of E1Bp at an E:T ratio of
1:2 and stained for CD8 and intracellular IFN-. The data are presented
as the proportion of CD8 IFN- producing cells to the total number of
CD8 cells and represent one of three independent experiments.
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complexes as well as their binding affinity plays an
important role in determining the antigenicity of the pep-
tide (Burg et al., 1996; Busch and Pamer, 1998). There-
fore, the stability of the complexes formed by Db and
single alanine-substituted E1Bp variants was assessed.
RMA-S cells were incubated with each peptide overnight
allowing sufficient peptide binding to class I MHC mol-
ecules on the cell surface and then were incubated
further in fresh medium after removing the peptide. At
each indicated time point, RMA-S cells were stained with
anti-Db antibody and the extent of decay was measured
by flow cytometry. In contrast to their similar binding
affinity to Db, the dissociation rates of the E1Bp variants
appeared distinctive in some variants (Fig. 3B). B1a or
B9a, which were substituted at position 1 (P1, Val) or
position 9 (P9, Ile) of the E1Bp with alanine, respectively,
showed high dissociation rates, indicating that the com-
plexes formed with B1a or B9a were relatively unstable.
This result suggests that the P1 or P9 residue of E1Bp
could serve as a minor anchor residue to the Db mole-
cules, which is consistent with findings of previous re-
ports (Young et al., 1994). In contrast, alanine substitution
at position 6 (P6, Cys) resulted in the most delayed
dissociation from the MHC molecules, even though it
was not a good binder to Db, as shown in Fig. 3A.
Consequently, P1 and P9 would be expected to influence
the antigenic sensitivity of the wild-type peptide because
substitution of their residues resulted in reduced stability
of the peptide–MHC complexes. Nevertheless, they are
not likely to directly affect TCR recognition.
The E1Bp variants were tested in a standard 51Cr
release assay using splenocytes obtained directly from
Ad5 immune mice. Although the results of this assay
show a summation of the lytic activity of polyclonal CTLs
encompassing the whole E1Bp-specific T cell repertoire,
it would have an implication for predicting the dominant
TCR contact residue of E1Bp recognized by E1Bp-spe-
cific T cells generated in vivo. As shown in Fig. 4, sub-
stitution at P4, P6, and P7 most strikingly affected pep-
tide recognition by the E1Bp-specific CTLs, since they
barely lysed the target cells pulsed with B4a, B6a, or B7a.
Substitution at P8 also influenced CTL recognition, but to
a lesser degree, and the other positions were marginally
affected. Since these substitutions did not affect the Db
binding affinity or stability of the peptide–MHC com-
plexes, as shown Fig. 3, the corresponding wild-type
residues seem to play an important role in TCR contact.
These results are also consistent with the putative TCR
contact residues predicted from the three-dimensional
FIG. 4. Ex vivo CTL assays to peptide variants. Splenocytes obtained
from Ad5-immune mice were subjected to cytotoxicity assays as de-
scribed in Fig. 1A. EL-4 cells pulsed with 10 M E1Bp or each peptide
variant were used as targets. The lysis values shown at the indicated
E:T ratios represents the average of triplicate experiments.
FIG. 3. Binding of E1Bp variants to H-2Db and stability of the peptide/
MHC complexes. (A) Binding of single alanine-substituted E1Bp vari-
ants to H-2Db was tested using RMA-S cells. RMA-S cells were incu-
bated with the indicated concentrations of E1Bp or E1Bp variants for
3 h. The cells were stained with mAb to H-2Db and analyzed by flow
cytometry. (B) Dissociation of variants from H-2Db was tested using
RMA-S. After overnight incubation of RMA-S with each peptide, the
cells were removed from the peptides and incubated further in fresh
RPMI medium at 37°C. At the indicated time points, the cells were
stained with mAb to H-2Db and analyzed by flow cytometry.
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crystal structure of the H-2Db (Young et al., 1994) and
computer modeling of the binding between E1Bp and
H-2Db (data not shown). Overall, it is quite likely that P4,
P6, and P7 of E1Bp serve as major TCR contact sites,
and P8 is also important for TCR contact of the E1Bp-
specific CTLs.
Similar experiments were performed using clones to
confirm the putative TCR contact sites identified with
E1Bp-specific polyclonal CTLs at the clonal level and to
analyze the fine functional specificity of the clones. They
revealed that the individual clones showed distinct re-
sponse patterns to the E1Bp variants. A panel of nine
CTL clones could be divided into four groups according
to their fine specificities in recognizing the E1Bp variants
(Fig. 5). Group 1 responded only to the wild-type peptide,
E1Bp, but not to other variants. Group 2 recognized only
B7a among the variants and more efficiently than E1Bp.
The CTL clones of these two groups showed a highly
restricted specificity to the wild-type peptide. In contrast,
clones belonging to group 3 and group 4 responded to
several variants, including B6a and B7a.
A recent report demonstrated that the functional spec-
ificity of the CTL clone was determined at the TCR level
(Ishikawa et al., 1998). TCR  chain usage was analyzed
to examine if the different functional specificities of the
clones were due to their different types of TCR molecules
by using RT–PCR and anti-TCR V monoclonal antibod-
ies. It was revealed that each of the nine CTL clones
expressed one of five different V chains (Table 1). How-
ever, clones belonging to a certain group classified by
functional analysis described above did not always have
the same TCR V chain. In particular, three individual
clones of group 1 displayed three different V usages,
while the clones of groups 3 and 4 expressed the same
V chain. These results suggest that the standard 51Cr
release assay using single alanine-substituted variants
was not effective enough to differentiate the fine func-
tional specificity of clones.
E1Bp-specific CTL clones are further divided into
subgroups depending on their fine functional
specificity defined by agonism assays
It has been reported that a high level of flexibility is an
essential feature of TCR, although the TCR recognition of
a ligand is highly specific (Mason, 1998). Particularly,
substitutions in the residues that are not the TCR contact
sites of a peptide frequently do not affect their antige-
nicity (Mason, 1998). However, in this study, the clones of
groups 1 and 2 showed highly restricted specificity to
E1Bp. Furthermore, these clones did not respond to B1a
and B9a, even though the residues are buried deeply in
the MHC molecules, so that they do not appear to affect
recognition by TCR. This is an unusual feature consider-
ing the general characteristics of the TCR exhibiting
substantial flexibility in ligand recognition. We examined
the possibility that the density of variant peptide–MHC
complexes on the target cell during the cytotoxicity assay
was not high enough to induce cytolysis for certain
clones of groups 1 and 2. Faster dissociation of B1a or
B9a from the peptide–MHC complexes than the wild-type
peptide as determined by destabilizing assay (Fig. 3B)
also supported this possibility. Thus, the agonism assay
was performed for each clone as described under Ma-
FIG. 5. Peptide specificity of E1Bp-specific clones. Nine CTL clones
were subjected to standard 51Cr release assays against peptide vari-
ants. EL-4 cells pulsed with 10 M E1Bp or each variant peptide were
incubated with the CTL clone at the E:T ratio indicated. They were
divided into four groups according to the patterns of recognizing pep-
tide variants, and each panel represents the data of a clone included in
each group.
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terials and Methods, which gives the CTL clones a
chance to contact sufficient amounts of antigens during
the cytotoxicity assay because the effector cells were
incubated with the target cells in the continuous pres-
ence of the peptide. Indeed, clones that had displayed a
restricted specificity to the wild-type peptide responded
to more variant peptides, including B1a and B9a (Fig. 6).
In other words, under this assay condition, some variant
peptides could fully sensitize target cells and thus suffi-
ciently stimulate CTL clones. Three clones of group 1
with similar specificity recognizing only wild-type peptide
in a standard 51Cr release assay responded indepen-
TABLE 1
Diversity in the Fine Specificities of E1Bp-Specific CTL Clones
Group Clone Agonistic APL-1a Agonistic APL-2b Antagonistic APLc TCR V usaged
1 5A3 — B1a, B2a — V7
1 2F2 —
B1a, B2a, B3a, B4a,
B9a B6a, B7a, B8a V15
1 2F3 — B1a, B2a, B3a, B9a — V3
2 5D2 B7a B1a, B3a, B7a, B9a B2a, B4a, B6a, B8a V8
3 5F11
B1a(/), B2a, B3a,
B6a, B7a, B9a
B1a, B2a, B3a, B6a,
B7a, B9a B4a, B8a V12
4 5F9-1 B2a, B6a, B7a, B9a
B2a, B3a, B6a, B7a,
B9a B4a, B8a V12
4 5F10
B2a, B3a(/), B6a,
B7a, B9a
B2a, B3a, B6a, B7a,
B9a B4a, B8a V12
4 5F13 B2a, B6a, B7a, B9a
B2a, B3a, B6a, B7a,
B9a B4a, B8a V12
4 5F14-1 B2a, B6a, B7a, B9a
B2a, B3a, B6a, B7a,
B9a B4a, B8a V12
a Determined by a standard 51Cr release assay.
b Determined by agonism assay.
c Determined by antagonism assay.
d Determined by RT–PCR and flow cytometry using TCR V-specific mAb.
FIG. 6. Peptide specificity of the E1Bp-specific clones determined by agonism assays. Nine CTL clones were subjected to agonism assays as
described under Materials and Methods. 51Cr-labeled EL-4 cells were incubated with the CTL clone in the presence of 10 M peptide at an E:T ratio
of 3:1. Each panel shows the data of clone indicated at the top of the panel.
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dently with a different recognition pattern to the variant
peptides in agonism assays. For example, clone 5A3
recognized B1a and B2a as agonists and clone 2F3
recognized B1a, B2a, B3a, and B9a as agonists. Surpris-
ingly, B4a, which has a substitution at the putative TCR
contact residue with alanine, served as an agonist for
clone 2F2, while it did not stimulate any of the other
clones. Thus clone 2F2 recognized B4a as well as B1a,
B2a, B3a, and B9a as agonists. Clone 5D2 of group 2
also showed a unique TCR recognition pattern. It was not
stimulated by B2a, which acted as an agonist for all the
other clones in the agonism assay, but was activated by
B1a, B3a, B7a, and B9a. Clone 5F11 of group 3 was
activated by all the variant peptides except B4a and B8a,
consistent with the results of a standard 51Cr release
assay. It showed a higher responsiveness to B1a and
B9a. Clone 5F10 recognized B3a and B2a, B6a, B7a, and
B9a as agonists in this assay. The other members of
group 4 responded similarly (data not shown).
Collectively, four groups of E1Bp-specific CTL clones
classified based on the functional differences of re-
sponse in a standard 51Cr release assay could be divided
into six groups according to their different fine specific-
ities determined by the agonism assay. This analysis
provided further evidence for the functional diversity of
the E1Bp-specific T cell repertoire.
Clones with different peptide specificity were
antagonized by different peptide variants
It has been reported that alterations in the TCR contact
residues of the epitope peptides could generate antag-
onist ligands that inhibit the T cell response to cognate
antigenic peptides (James et al., 1993). Since the panel of
E1Bp-specific clones used in this study responded to the
single alanine-substituted variants of E1Bp with varying
specificities, the TCR contact residues of the E1Bp pep-
tide might be accommodated in different ways in individ-
ual clones. A clone could be antagonized most efficiently
by a variant with substitutions at the residues for TCR
contact. To examine this possibility, an antagonism as-
say for nine clones was performed using variants that
were not stimulatory in the agonism assay. B4a and B8a,
which were nonstimulatory to most of the clones, includ-
ing 5F10, turned out to be antagonistic to 5F10, since
they inhibited the lysis of target cells pulsed with sub-
optimal concentrations of wild-type peptides in a dose-
dependent manner (Fig. 7). This antagonism appears to
be due to antigen-specific inhibition but not to any other
factor, such as a simple MHC blockade, since an irrele-
vant Db binding peptide, E1Ap, showed no inhibition. As
summarized in Table 1, all the clones belonging to
groups 3 and 4 also exhibited an antagonism pattern
similar to that of 5F10. B6a, B7a, and B8a antagonized
2F2. Although P7 as well as P6 and P8 was regarded as
an important residue for TCR contact, B7a served as an
agonist as effectively as the wild-type peptide for all
clones tested except those of group 1. Moreover, B2a as
well as B4a, B6a, and B8a antagonized 5D2. It is surpris-
ing that B2a acted as an antagonist since P2 of the
peptide is likely to be irrelevant to TCR recognition. In
fact, it stimulated all the E1Bp-specific clones except 5D2
in the standard Cr51 release assay. Taken together, these
results suggest that E1Bp-specific CTL clones varied
greatly in their ability to recognize E1Bp, reflecting a
striking degree of diversity in the TCR repertoire specific
to the same antigen.
Clonal diversity of E1Bp-specific T cells seems to be
increased when compared with that of the ex vivo
repertoire
The CTL clones when compared with the polyclonal
CTLs exhibited different patterns in response to E1Bp
variants in that the responsiveness to B1a or B9a was
considerably reduced or abolished, while B6a or B7a
FIG. 7. Diverse patterns of TCR antagonism. Antagonism assays were performed with CTL clones. 51Cr-labeled EL-4 cells were pulsed with
suboptimal concentrations of wild-type peptide and incubated with CTL clones in the presence of various concentrations of peptide variants at an
E:T ratio of 3:1. The data represent one of three independent experiments.
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could be recognized by many of them in cytotoxicity
assays (Fig. 5). In particular, B7a was recognized to a
similar extent as or more efficiently than that with the
wild-type peptide by most of the clones except those of
group 1, whereas it was poorly recognized by the poly-
clonal CTLs generated from the Ad5-immune mice (Figs.
4 and 5). Previous reports demonstrated that in vitro
expansion of T cells lead to a marked bias in the TCR
repertoire specific to a given antigen (Gamon et al., 1990;
Busch and Pamer, 1998; Mazzanti et al., 2000). This could
provide a possible explanation for the discrepancy in fine
specificity between polyclonal CTLs derived directly from
Ad5-immune mice and the CTL clones established in
experimental conditions in this study, including repeated
in vitro stimulation. In this regard, V usage of the E1Bp-
specific repertoire induced in vivo by Ad5 immunization
was analyzed and compared with those of the CTL
clones. Splenocytes secreting IFN- in response to an-
tigenic stimulation were analyzed by triple staining with
anti-CD8 Ab, anti- IFN- Ab, and a panel of anti-TCR V
Abs. The E1Bp-specific T cell populations induced in vivo
predominantly expressed TCR V8.1/2 and V5.1/2, con-
trary to the V phenotypes expressed by the most of the
clones (Fig. 8). These results suggested that the E1Bp-
specific T cell repertoire induced in vivo was selected
into particular subpopulations during in vitro stimulation,
from which the CTL clones were established. It is very
likely that the E1Bp-specific CTL repertoire induced in
vivo is more diverse than what is reflected by those
observed with T cell clones established in this study.
DISCUSSION
While most infections are self-controlling and asymp-
tomatic in healthy individuals, adenoviruses are involved
in a wide variety of clinical symptoms in immunocompro-
mised patients with significant morbidity and mortality
(Carrigan, 1997; La Rosa et al., 2001). This suggests that
immunodeficiency status is a critical cause of disease
and implies that reconstitution of cellular immunity is
important for treating severe adenovirus infection. Adop-
tive immunotherapy using unmanipulated donor lympho-
cytes has been performed in bone marrow transplant
patients with encouraging results (Howard et al., 1999;
Shakrabarti et al., 2000; Bordigoni et al., 2001). On the
other hand, human adenovirus type 5 has widely been
used as a recombinant vector for human gene transfer.
However, transgene expression from the adenoviral vec-
tors appears to be limited due to preexisting or newly
developed host immune responses against the vectors.
It should be noted that more than 90% of adults have
experienced an infection with common adenovirus sero-
types, including Ad5, and have acquired humoral and
cellular immunity (Piedra et al., 1998; Mazzanti et al.,
2000). Therefore, the precise characterization of the CTL
responses elicited by an immunodominant epitope of the
adenovirus might be important for understanding the
adenoreactive immune response.
In this study, CTL clones specific for E1Bp were gen-
erated by in vitro restimulation of splenocytes harvested
from Ad5-immune C57BL/6 mice. Although it has been
reported that Ad5-specific CTL response is exclusively
directed to the Ad5E1A-encoded epitope E1Ap, E1Bp-
specific CTLs were also generated efficiently in mice
introduced to the E1 antigen in the form of the whole Ad5
virus. This suggests that E1Bp could serve as one of the
immunodominant Ad5-derived CTL epitopes when whole
viruses were immunized, which is consistent with a pre-
vious report that the E1-bearing tumor cells used as an
immunogen induced E1Bp-specific CTL (Toes et al.,
1995).
The E1Bp-specific CTL clones established in this
study showed extremely diverse specificities, as deter-
mined with the altered peptide ligands generated by
single alanine substitution. In particular, B4a was an
agonist to clone 2F2, whereas it was antagonistic to
most of the other clones. It was also interesting that 5D2
recognized B2a as an antagonist, since the residue at
position 2 is likely to have little impact on the association
with TCR due to its structural constraint imposed by the
-helix of the H-2Db molecule. TCR of 5D2 might provide
the binding peptide with a molecular environment that is
different from that of the TCR of other clones, resulting in
a different specificity. These results appear to be consis-
tent with previous reports that CTL response to a single
viral epitope was quite diverse at the clonal level
(Casanova et al., 1991; Horwitz et al., 1994; Ishikawa et
al., 1998).
Several in vivo applications for treating various auto-
immune diseases using TCR antagonists have not been
successful, although their efficacy in inhibiting the re-
sponses induced by the cognate peptide was thoroughly
FIG. 8. Analysis of an E1Bp-specific TCR V repertoire induced in
vivo. C57BL/6 mice were immunized with 1  1010 PFU of Ad5. Nine
days later, splenocytes (2 106) from the immune mice were incubated
with 10 M peptide in the presence of monensin and 50 U/ml of hIL-2
for 5 h. The cells were stained for CD8, TCR V, and intracellular IFN-.
Each bar indicates the percentage of IFN--secreting CD8 T cells
stained with the individual TCR V-specific antibody among total IFN-
-secreting CD8 cells. Error bars represent standard deviations of the
data obtained from three mice. The mean percentage of T cells secret-
ing IFN- among total CD8 T cells was 7.9%.
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investigated in vitro (Anderton et al., 1998). The reasons
for this failure involve the fact that antagonists identified
in vitro using a limited number of T cell clones or hybrid-
omas could activate and mobilize T cells of different fine
specificities in vivo where extremely diverse TCRs are
expressed (Anderton et al., 1998). In this regard, our
findings that a variant peptide serving as an agonist for
some Ag-specific population could antagonize the re-
sponses of other populations with a similar antigenic
specificity, or vice versa, imply that antagonist-based
immunotherapy may not be feasible for clinical applica-
tion in individuals with extremely complex and diverse T
cell repertoires.
It is noteworthy that the responses to the variant pep-
tides B1a and B9a showed different patterns between
E1Bp-specific polyclonal CTLs and CTL clones. Few of
the clones established in this study responded to the
peptides, while the polyclonal CTLs responded to these
variant peptides to a similar extent to that of the wild-type
peptide. This might have resulted from the selection of
the CTL population with low or no responsiveness to B1a
or B9a during the cloning process under these experi-
mental conditions. This assumption was supported by
the result that the polyclonal CTLs stimulated once in
vitro with E1Bp showed considerably decreased respon-
siveness to B1a and B9a compared with the ex vivo
polyclonal CTLs without in vitro stimulation (data not
shown). These E1Bp peptide residues appeared to play
an important role in producing a stable complex with the
MHC molecules rather than in interacting with the TCR,
considering the structural characteristics and the result
of the dissociation assay of the peptide–MHC complex
(Fig. 3). These observations suggest that the CTLs with
low-affinity TCR among the E1Bp-specific T cell reper-
toire might have been selected during in vitro stimula-
tion, since the clones that did not recognize the peptides
in a standard 51Cr release assay could respond to the
same peptides in the agonism assay where higher con-
centrations of antigens were available. In this regard, the
diversity of the E1Bp-specific CTL repertoire estimated
from the clonal fine specificity in this study is not likely to
reflect the in vivo repertoire itself. This notion was also
supported by the observation that TCR V usage of an ex
vivo repertoire specific to E1Bp was different from those
of CTL clones.
In conclusion, these results suggest that the functional
diversity of the in vitro expanded CTLs responding to a
single peptide epitope should be taken into account for
developing safe and efficient adoptive immunotherapy
for immunocompromised individuals. In addition, the de-
velopment of novel vectors, which would not be influ-
enced by the host memory immunity acquired from in-
fection with common Ad, might be required for efficient
gene transfer, as shown in recent studies (Rasmussen et
al., 1999; Kremer et al., 2000) evaluating animal adeno-
virus vectors as an alternative to human adenovirus
vectors.
MATERIALS AND METHODS
Cells, viruses, and mice
EL-4, RMA-S, P815, LB, and YAC-1 cells were pur-
chased from the American Type Culture Collection
(Rockville, MD). All cells were cultured at 37°C with 5%
CO2 in a RPMI 1640 medium (Gibco BRL, Grand Island,
NY) supplemented with 10% fetal bovine serum (FBS;
Gibco BRL), 2 mM L-glutamine, 100 U/ml of penicillin G,
100 g/ml of streptomycin, 250 ng/ml of amphotericin B,
10 mM HEPES, 24 mM Na2HCO3, and 50 M 2-mercap-
toethanol. Ad5 was kindly provided by Dr. D. Lim (KRIBB,
Taejeon, Korea) and was propagated in 293 cells, and its
plaque forming unit (PFU) was determined as previous
described (Duerksen-Huges et al., 1989). The viruses
were stored at 70°C until used. C57BL/6 mice were
obtained from Daehan Laboratory Animal Research Cen-
ter (Eumsung, Korea) and kept under the specific patho-
gen-free conditions. Male or female mice were used for
the experiments at 6 to 8 weeks of age.
Synthetic peptides
A peptide (E1Bp; VNIRNCCYI) derived from the
Ad5E1B region and its single alanine-substituted variant
peptides were synthesized by solid-phase synthesis. The
synthetic peptides were purified to 95% purity by re-
verse-phase HPLC. All peptides were dissolved in 20%
DMSO at a concentration of 10 mM.
Peptide binding assay
The affinity of peptides to Db molecules was measured
as previously described (Lim et al., 1996). RMA-S cells
were incubated with various concentrations (106–10
M) of synthetic peptides for 3 h at 37°C. After washing
twice with Dulbecco’s phosphate-buffered saline (PBS;
Sigma, St Louis, MO) supplemented with 1% bovine se-
rum albumin (Sigma), 100 l of culture supernatant of
28-11-5S (ATCC HB19) containing anti-Db antibody was
added and incubated for 30 min on ice. The cells were
then washed three times and incubated with 0.1 g of
fluorescein isothiocyanate (FITC)-conjugated goat anti-
mouse immunoglobulin (GAMIg-FITC; Biosource, Cama-
rillo, CA) for 30 min on ice. After washing, the cells were
immediately fixed with 1% paraformaldehyde in PBS.
Fluorescence intensity was measured with a flow cytom-
eter (Becton–Dickinson, San Jose, CA).
Peptide dissociation assay
The stability of the MHC/peptide complex was mea-
sured as described previously (Busch and Pamer, 1998).
Briefly, RMA-S cells were incubated with 10 M peptides
overnight at 37°C. The cells were washed three times
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with Hanks’ balanced salt solution (HBSS; Gibco BRL)
and resuspended in RPMI medium (5  105 cells/ml).
Subsequently, the cells were further incubated for the
indicated time period at 37°C and then stained with 100
l of the 28-11-5S supernatant and subsequently with
GAMIg-FITC. H-2Db expression was determined by flow
cytometry.
Immunization and generation of CTL clones
Groups of mice (two or three mice per group) were
intraperitoneally injected with 2  109 PFU of Ad5. After
2 or 3 weeks, the spleens were removed from the immu-
nized mice and were generated into single cell suspen-
sions in HBSS. After washing with HBSS, red blood cells
(RBC) were lysed by incubating with RBC lysis buffer
(0.017 M Tris base and 0.144 M NH4Cl) at 37°C for 5 min.
The resulting splenocytes were cultured with E1Bp (2
M) to induce polyclonal E1Bp-specific CTL populations.
To generate CTL clones, they were further restimulated
weekly with syngenic splenocytes treated with 50 g/ml
of mitomycin C (Sigma) in the presence of the peptide
and 2.5% concanavalin-A-activated rat spleen culture su-
pernatant (CAS) as a source of IL-2. The resulting poly-
clonal CTL populations were plated in 96-well round-
bottom plates containing mitomycin-C-treated syngeneic
splenocytes (2  105 cells), 2 M peptide, and 2.5% CAS
at 0.3–5 cells per well. When the frequency of the micro-
wells containing growing cells at a given cell dilution
was less than 20%, the proliferating cells of the culture
plate were chosen for further expansion and tested for
their antigenic specificity using a standard cytotoxicity
assay. The CTL clones obtained were maintained by
weekly restimulation.
Cytotoxicity assay
Cytotoxicity was measured in a standard 4-h 51Cr re-
lease assay. Briefly, target cells were labeled with 25
Ci/ml of Na2
51CrO4 (NEN, Boston, MA) for 1 h at 37°C,
washed with HBSS, and pulsed with the peptide at the
indicated concentrations for 1 h in RPMI 1640 medium.
The washed target cells were plated with effector cells in
a microtiter assay plate at an indicated effector:target
(E:T) ratio and incubated for 4 h at 37°C. For direct ex
vivo analysis, incubation was performed for 8 h. Radio-
activity in the supernatant was then determined by -ra-
diation counting. The specific lysis was determined us-
ing the formula [(experimental release  spontaneous
release)/(maximum release  spontaneous release)] 
100. All experiments were performed in triplicate and the
spontaneous release was always less than 10% of the
maximum release.
For the agonism assay, effector cells were plated with
the peptide (10 M) and the 51Cr-labeled EL-4 target cells
and then incubated for 4 h at 37°C using the above
described procedure.
Antagonism assay
51Cr-labeled target cells were incubated with a subop-
timal concentration of the wild-type peptide E1Bp, which
is accommodated with a range of 0.05–1 M according
to the antigenic sensitivity of the individual clone tested
by a standard 51Cr release assay. After washing, the
target cells (1  104/well) were further incubated with
various concentrations of variant peptides for 1 h at 37°C
in a microtiter plate. The CTL clones were subsequently
added at an E:T ratio of 2:1. The subsequent procedure
was performed as described for the cytotoxicity assay.
The inhibition of lysis was calculated by the formula
percentage of inhibition  100  [1  (percentage of
lysis in the presence of inhibitor/percentage of lysis in
the absence of inhibitor)].
Intracellular IFN- assay
An intracellular IFN- assay was performed as de-
scribed previously (Itoh et al., 1997). The CTL clones (5
105 cells), which were rested for 1 week or more from the
antigenic stimulation, were incubated with EL-4 cells
(1  106 cells) pulsed with various E1Bp concentrations
in the presence of a protein transport inhibitor, monensin
(Pharmingen, San Diego, CA), for 5 h at 37°C. After
incubation, the cells were washed with PBS containing
0.5 mM EDTA and stained with FITC-conjugated anti-TCR
V Ab (Pharmingen) and Cy-Chrome-conjugated anti-
CD8 Ab (Pharmingen) for 30 min on ice. After washing
with PBS, the cells were treated with PBS containing 4%
paraformaldehyde for fixing for 5 min at 37°C and
washed once with PBS containing 1% BSA. After two
additional washes with PBS (0.1% BSA, 0.1% saponin, and
0.01 M HEPES), the cells were stained with PE-conju-
gated anti-IFN- antibody (Pharmingen) for 30 min on ice
and washed twice with PBS (0.1% BSA, 0.1% saponin, and
0.01 M HEPES). T cells were gated on FSC/SSC param-
eters and the percentages of IFN- T cells of CD8 T
cells were analyzed using the CELLQUEST program.
TCR V chain analysis
TCR V chain usage of CTL clones was analyzed by
polymerase chain reaction (PCR) and confirmed by FACS
analysis. For PCR analysis, the total RNA was isolated
from 5  106 CTL clones using Trizol (Gibco BRL) ac-
cording to the manufacturer’s instruction and used for
single-stranded cDNA synthesis with oligo(dT)15 (Pro-
mega, Madison, WI) and 200 Units of MuLV reverse
transcriptase (Promega). PCR was performed using the
cDNA of each clone with 0.25 mM dNTP, 1.0 Unit of Taq
polymerase (Ex-Taq; Takara, Otsu, Shiga, Japan), and 19
V-family-specific primers. Amplification was carried out
under melting conditions of 95°C for 30 s, annealing at
each annealing temperature for 30 s, and extension at
72°C for 30 s, which was repeated for 35 cycles. They
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were then analyzed on a 1% agarose gel stained with
ethidium bromide. The TCR V usage of the CTL clones
determined by PCR was confirmed by using anti-TCR V
antibodies specific to each TCR V phenotype.
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